Search
Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … Dostarlimab is an IgG<sub>4</sub> humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalSugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. … [L53333] The drug achieves this through a dual mechanism of action involving binding to the programmed cell death-ligand 1 (PD-L1) and also through inducing antibody-dependent cellular phagocytosis.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsTacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparatio...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsProducts: Envarsus PaHuman immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIntravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and io...
Products: INTRAGAM P, BERIGLOBINA - PDasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigationalDasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. … [A11377] Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAdenosine
go.drugbank.com/drugs/DB00640ApprovedInvestigationalThe structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though i...
Mixtures: BOTA C Reset, The Prestige BB SPF25 PA 2PlusCategories: Purinergic P1 Receptor AgonistsSodium bicarbonate
go.drugbank.com/drugs/DB01390ApprovedInvestigationalSodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
Vusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigational] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on a PD … L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed on anti-PD
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41305] As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational-1/PD-L1 inhibitor therapy. … [L64775] On July 29, 2026 it extended the authorization to first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy
Categories: P-glycoprotein substrates